NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced that the company will participate in the
Jefferies 2016 London Healthcare Conference in London, UK.
Revance management is scheduled to present on Wednesday, November 16 at
Interested parties can access the live audio webcast for both of these
conferences from the Investor Relations section of the company's website
The webcast replay will be available after the conclusion of the live
presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology and neurology. Revance's science is
based upon a proprietary TransMTS® peptide technology, which when
combined with active drug molecules, may help address current unmet
needs. Revance's initial focus is on developing daxibotulinumtoxinA, the
company's highly purified botulinum toxin, for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles and
muscle movement disorders.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis and has the potential to
be the first long-acting neurotoxin. The company holds worldwide rights
for all indications of RT002 injectable and RT001 topical and the
pharmaceutical uses of the TransMTS technology platform. More
information on Revance may be found at www.revance.com.
"Revance Therapeutics", TransMTS®, "Remarkable Science Changes
Everything", and the Revance logo are registered trademarks of Revance
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107006165/en/
Jeanie Herbert, 714-325-3584
Ami Bavishi, 212-213-0006
Nadine Tosk, 504-453-8344
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media